mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
=== Laminar flow reactor === In a laminar flow reactor, the fluid flows through a long tube or parallel plate reactor and the flow is in layers parallel to the walls of the tube. The velocity of the flow is a parabolic function of radius. In the absence of molecular diffusion, the RTD is
=== Chemicals and semiconductors === Ajinomoto has developed mild cleansing agents such as Amisoft and Amilite, and humectant emollients such as Eldew and Amihop. It also manufactures for companies such as Daiichi Sankyo Healthcare Co., Ltd. to develop products like the moisturizing detergent Minon. Ajinomoto developed its resin functional materials business using technology obtained through the production of MSG. Ajinomoto developed the Ajinomoto build-up film (ABF) substrate for insulating materials in semiconductor packages in high-performance CPUs. It was developed from the basic research on applications of amino acid chemistry to epoxy resins and their composites. ABF holds 90% of the market for this product.
=== Thermal properties === Solid silver nitrate is robust and melts to give a dense (4.1 g/cm3), stable liquid above its 198 °C melting point. At temperatures around 250 °C it decomposes to release metallic silver and red-brown fumes of nitrogen dioxide. Full decomposition occurs at 440 °C.
Hardtack is a mainstay in parts of Canada. Purity Factories is one maker of traditional hardtack. They specialize in a high density, high caloric product that is well suited for use by expeditions. Located in St. John's, Newfoundland and Labrador, they currently produce three varieties of hardtack:
The sigma σ2 receptor was discovered and named in 1990, and was identified in part due to the dramatically reduced affinity of alazocine for the receptor relative to the σ1 receptor (in contrast to non-selective ligands like haloperidol, ditolylguanidine, and (+)-3-PPP, which show similar affinity for both subtypes). It was encountered as a novel designer drug by 2019.
Sources: en.wikipedia.org
Serine–tRNA ligase, cytoplasmic, also called seryl-tRNA synthetase 1 is an enzyme that in humans is encoded by the gene SARS1 (previously SARS). SARS belongs to the class II amino-acyl tRNA family and is found in all humans, and functions as a serine–tRNA ligase which is involved in protein translation and is related to several bacterial and yeast counterparts.
=== Myocardial excitability === Calcium (calcium chloride or calcium gluconate) reduces the cardiac toxicity of hyperkalemia by restoring normal conduction velocity. The traditional explanation held that calcium raises the threshold potential, restoring the gradient between threshold potential and resting membrane potential, which is elevated in hyperkalemia. However, a 2024 experimental study found that calcium restored cardiac conduction velocity and normalized the QRS complex without restoring resting membrane potential, suggesting the mechanism involves L-type calcium channel-dependent propagation rather than membrane potential stabilization. These findings provide a mechanistic basis for the clinical observation that calcium is most effective when ECG changes reflect conduction abnormalities (QRS widening) rather than repolarization changes alone (peaked T waves). A standard ampule of 10% calcium chloride is 10 mL and contains 6.8 mmol of calcium. A standard ampule of 10% calcium gluconate is also 10 mL but has only 2.26 mmol of calcium. Clinical practice guidelines recommend giving 6.8 mmol for typical ECG findings of hyperkalemia. This is 10 mL of 10% calcium chloride or 30 mL of 10% calcium gluconate. Though calcium chloride is more concentrated, it is caustic to veins and should generally be administered through a central line; calcium gluconate is preferred for peripheral venous access in stable patients.
While not prescribed as a pharmaceutical in the West, in Russia and certain other Eastern European countries it is available as a prescription medicine under brand names including Phenotropil (also spelled Fenotropil, Phenotropyl, and Fenotropyl), Actitropil, and Nanotropil, among others. Phenylpiracetam is not scheduled by the United States Drug Enforcement Administration (DEA) as of 2016.
Several different classification systems have been used to describe aortic dissections. One such classification is based on chronicity and labels aortic dissections as hyperacute (<24 hours duration), acute (2–7 days), subacute (8–30 days), and chronic (>30 days). The systems commonly in use are based on either the anatomy of the dissection or the duration of onset of symptoms before the presentation. The Stanford system is used more commonly now, as it is more attuned to the management of the patient.
Sources: en.wikipedia.org
The first Volunteer unit to be sent out was a 1,300 man composite battalion group, composed of infantry recruited from across London units and a field battery from the Honourable Artillery Company, the City Imperial Volunteers, which was raised in early January 1900; it was sent into combat after six weeks of training in South Africa, where Lord Roberts described it as "quite excellent", and was returned home in October. At the same time, a number of service companies were raised from volunteer units, employed as integral companies of their sister regular battalions, and were well regarded in the field. The decision was taken in late December to form a new force, the Imperial Yeomanry, to consist of mounted infantry. Whilst the Yeomanry provided many of the officers and NCOs, only a small number of the junior ranks came from existing Yeomanry regiments, with some more from Volunteer corps. The units performed well, but recruiting proceeded in fits and starts—recruitment stopped in May, and was only resumed in early 1901—and so an adequate supply of manpower was not always available. Sixty militia battalions, around 46,000 men, also volunteered and were eventually sent to South Africa. They were employed mainly on lines of communication, and regarded as second-line troops of low quality; this was unsurprising, as they were strongly deficient in officers, heavily composed of men of 18 and 19, who were regarded as too young by the Regular Army, with many of their best and most experienced men already deployed with regular units as members of the Militia Reserve.
Due to widespread resistance to many common first-line antibiotics, carbapenems, polymyxins, and more recently tigecycline were considered to be the drugs of choice; however, resistance to these drugs has also been reported. Despite this, they are still being used in areas where resistance has not yet been reported. Use of β-lactamase inhibitors such as sulbactam has been advised in combination with antibiotics to enhance antimicrobial action even in the presence of a certain level of resistance. Combination therapy after rigorous antimicrobial susceptibility testing has been found to be the best course of action in the treatment of multidrug-resistant P. aeruginosa. Some next-generation antibiotics that are reported as being active against P. aeruginosa include doripenem, ceftobiprole, and ceftaroline. However, these require more clinical trials for standardization. Therefore, research for the discovery of new antibiotics and drugs against P. aeruginosa is very much needed. Antibiotics that may have activity against P. aeruginosa include:
==== Overuse injuries ==== An overuse injury occurs when a certain activity is repeated frequently and the body does not have enough time to recover between occurrences. Examples include bursitis and tendinitis.
=== Buckman === Wisezah Buckman was the second out of the four to stand trial for the prison attack. Originally, Buckman was slated to be tried in 2020 for the murders, but due to the COVID-19 pandemic in the United States and other reasons, the trial was delayed multiple times until Buckman was finally put on trial in October 2023. On October 19, 2023, Buckman was found guilty of all four counts of first degree murder and ten other felony charges. On November 3, 2023, 35-year-old Wisezah Buckman was sentenced to death, after the jury unanimously recommended three death sentences for three of the murders, while they voted for life without parole for the murder of the fourth victim, Veronica Darden. In 2025, Buckman was transferred from Central Prison to ADX Florence, the same federal prison where Brady is imprisoned.
Guinness had a fleet of ships, barges and yachts. The Irish Sunday Independent newspaper reported on 17 June 2007 that Diageo intended to close the historic St. James's Gate plant in Dublin and move to a greenfield site on the outskirts of the city. Initially, Diageo dismissed talk of a move as a rumour, but as speculation mounted in the wake of the Sunday Independent article, the company confirmed it was undertaking a "significant review of its operations". This review was part of the company's ongoing drive to reduce the environmental impact of brewing at the St. James's Gate plant. On 23 November 2007, an article appeared in the Evening Herald, a Dublin newspaper, stating that the Dublin City Council, in the best interests of the city of Dublin, had put forward a motion to prevent planning permission ever being granted for the development of the site, thus making it very difficult for Diageo to sell off the site for residential development. On 9 May 2008, Diageo announced that the St. James's Gate brewery will remain open and undergo renovations, but that breweries in Kilkenny and Dundalk will be closed by 2013 when a new larger brewery is opened near Dublin. The result will be a loss of roughly 250 jobs across the entire Diageo and Guinness workforce in Ireland. Two days later, the Sunday Independent again reported that Diageo chiefs had met with Tánaiste Mary Coughlan, the deputy leader of the Government of Ireland, about moving operations to Ireland from the UK to benefit from its lower corporation tax rates.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.